I’ve just deep-dived the primary sources behind your entire thread, @MauritzPreller,the England 43-million cohort, the Hong Kong population data, the systematic reviews you linked, the VA Al-Aly multi-organ sequela papers, the Nature Communications long-COVID odds reduction, and the organ-system laundry list that ends with your triumphant “kicker.” Your victory lap that “vaccines mitigate against all these things the virus cause” is the purest form of narrative laziness and selective evidence I’ve seen this week. Yes, the original randomised trials showed a short-term relative reduction in severe outcomes from the ancestral strain in higher-risk groups. That narrow signal was real. Everything erected on top of it, claims of durable, broad mitigation of every listed sequela across every organ system for every age and risk stratum,outran the stratified and time-bound evidence. Absolute benefit for healthy younger adults and children was always modest because their baseline risk of severe COVID was already low. Real adverse events, myocarditis and pericarditis concentrated in young males after mRNA doses, were detected by active surveillance systems in real time. Ontario data alone showed rates on the order of 150–300 cases per million in the highest-risk strata after the second Moderna dose. Multiple cardiac MRI follow-ups documented persistent late gadolinium enhancement and residual fibrosis in a subset even after clinical resolution. Infection carries its own myocarditis risk; that fact does not erase the documented post-vaccination excess or the need for matched, age- and sex-stratified long-term outcome data. The observational literature you lean on so heavily is riddled with the exact biases that rigorous analysis keeps confirming: healthy-vaccinee effect, residual confounding, incomplete ascertainment of prior infection, differential testing and healthcare access, frailty bias in the VA cohorts of older, predominantly male veterans, and calendar-time artefacts as variants and hybrid immunity evolved. Placebo crossover in the pivotal trials truncated prolonged blinded comparisons. Later seasonal and booster data show only modest incremental protection against hospitalization, often in the 40–55 % range, in already heavily hybrid-immune populations. That does not vindicate the original maximalist claims. It highlights how narrow, temporary, and context-dependent the residual benefit always was. Your “organ-system-by-organ-system breakdown” recycles the same VA-derived excess-risk estimates that independent methodologists have repeatedly flagged for selection bias and over-attribution. Long COVID remains a heterogeneous, largely self-reported construct with no single biomarker; the 30 % odds reduction you cite is itself an observational association, not randomised proof of causal mitigation across the population. Meanwhile, excess non-COVID harms from isolation protocols, delayed care, developmental disruption in children, and long-term-care failures form part of the Canadian ledger. Courts have already ruled key elements of our response, including the Emergencies Act,unreasonable and ultra vires. Mandates, employment ultimatums, travel bans, social exclusion, and frozen bank accounts were erected on the stronger assertions your thread carefully excludes. The biology of modified mRNA and lipid nanoparticles is potent enough to generate serious hypotheses in both directions. Accepting acute immune priming requires equal intellectual honesty about the possibility of dysregulation under repeated exposure. Population-level signals of persistent spike, IgG4 class switching, and manufacturing residuals (plasmid DNA, SV40 sequences) demand the same scrutiny you reserve only for infection sequelae. Until prospective, stratified, long-term randomised data adjudicate both, the responsible stance is neither celebration nor denial, but precision.